The Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Early Breast Cancer: Results of a Pre-Operative Study

Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-010-0967-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients With Relapsed Non Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2007English

Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin

Clinical Cancer Research
Cancer ResearchOncology
2008English

Combination Therapy for Treating Breast Cancer Using Antiestrogen, ERA-923, and the Mammalian Target of Rapamycin Inhibitor, Temsirolimus

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2006English

Metformin Inhibits Mammalian Target of Rapamycin Dependent Translation Initiation in Breast Cancer Cells

Cancer Research
Cancer ResearchOncology
2007English

New Targets for Therapy in Breast Cancer: Mammalian Target of Rapamycin (mTOR) Antagonists

Breast Cancer Research
Cancer ResearchOncology
2004English

Ku-0063794 Is a Specific Inhibitor of the Mammalian Target of Rapamycin (mTOR)

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2009English

Correction: An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-Resistant Functions of mTORC1.

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2020English

Inhibition of the Mammalian Target of Rapamycin (mTOR) in Advanced Pancreatic Cancer: Results of Two Phase II Studies

BMC Cancer
Cancer ResearchOncologyGenetics
2010English

Downregulation of Notch Pathway by a -Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model

Cancer Research
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy